Silexion Therapeutics: A Key Preclinical Data Milestone Nears

As investors, we're always on the lookout for transformative developments that can significantly impact a company's future. Silexion Therapeutics (SLXN) is on the cusp of such a moment, with anticipation building around its upcoming preclinical data. This data could be a game-changer, potentially revolutionizing the treatment landscape for KRAS-driven cancers, including pancreatic cancer.

Silexion's next-generation siRNA candidate, SIL-204, has shown promising results in preclinical studies, demonstrating a 50% reduction in tumor growth and complete necrosis in half of treated tumors in a G12D mutant pancreatic cancer model. This therapy targets a broader range of KRAS mutations, making it applicable across multiple cancer types, including colorectal and lung cancers. The company's collaboration with Evonik, a global leader in specialty chemicals, has resulted in a long-acting PLGA microparticle formulation for SIL-204, which has shown high efficacy in preclinical models for KRAS-mutated cancers.

The upcoming preclinical data is expected to validate the systemic administration approach for SIL-204, with effective drug levels maintained for over 56 days in rat plasma and tissues. This prolonged activity is crucial for maintaining therapeutic effects and minimizing the risk of drug resistance. The consistency in outcomes between the previous and upcoming data suggests that SIL-204's therapeutic effects are robust and reproducible across different models and experimental conditions.



Silexion's new preclinical data also reveals significant synergy between SIL-204 and first-line chemotherapy agents, such as 5-fluorouracil, irinotecan, and gemcitabine. This synergy underscores SIL-204's potential to enhance existing treatment regimens, addressing significant unmet needs across multiple oncology indications. The company plans to initiate toxicology studies with SIL-204 within the upcoming months and to advance it into Phase 2/3 clinical trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC).

As investors, we should be excited about the potential of SIL-204 and Silexion Therapeutics. The company's proven track record, broad applicability, synergistic efficacy, strong partnerships, robust preclinical data, and clear clinical milestones all align with an investment philosophy focused on stable, predictable, and consistent growth. While there may be challenges and risks along the way, the potential rewards of a successful transformative therapy like SIL-204 are too great to ignore.

In conclusion, Silexion Therapeutics is approaching a key preclinical data milestone that could be transformational for the company and the broader precision oncology space. As investors, we should keep a close eye on this development and consider the potential impact on our portfolios. The upcoming data could be a catalyst for significant growth and value creation for Silexion Therapeutics and its shareholders.